Research programme: radiolabelled antagonistic peptides - OctreoPharm

Drug Profile

Research programme: radiolabelled antagonistic peptides - OctreoPharm

Alternative Names: 177LU-OPS 201; OPS 201; SOMther

Latest Information Update: 11 Nov 2015

Price : $50

At a glance

  • Originator OctreoPharm Sciences
  • Class Peptides; Radiopharmaceuticals
  • Mechanism of Action Somatostatin receptor 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuroendocrine tumours

Most Recent Events

  • 11 Nov 2015 OctreoPharm plans a phase I/II trial in Neuroendocrine tumours in Australia, Austria, Denmark, Switzerland and the United Kingdom (NCT02592707)
  • 30 Jun 2015 Ipsen acquires OctreoPharm Sciences
  • 29 Jan 2014 Preclinical trials in Neuroendocrine tumours in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top